Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) EPS (Weighted Average and Diluted) (2016 - 2025)

Angiodynamics (ANGO) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with -$0.16 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 40.74% year-over-year to -$0.16, compared with a TTM value of -$0.67 through Nov 2025, up 87.99%, and an annual FY2025 reading of -$0.83, up 81.92% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.16 for Q4 2025 at Angiodynamics, up from -$0.26 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.15 in Q3 2023 and bottomed at -$4.67 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.42, with a median of -$0.22 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 448.48% in 2023, then crashed 1845.83% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.21 in 2021, then changed by 0.0% to -$0.21 in 2022, then plummeted by 242.86% to -$0.72 in 2023, then soared by 62.5% to -$0.27 in 2024, then surged by 40.74% to -$0.16 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ANGO at -$0.16 in Q4 2025, -$0.26 in Q3 2025, and -$0.14 in Q2 2025.